EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
Tumour heterogeneity and resistance to cancer therapies
I Dagogo-Jack, AT Shaw - Nature reviews Clinical oncology, 2018 - nature.com
Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …
[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
[HTML][HTML] Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway
Eradicating tumor dormancy that develops following epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer …
(EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer …
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib
GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - jamanetwork.com
Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
Antitumour immunity regulated by aberrant ERBB family signalling
S Kumagai, S Koyama, H Nishikawa - Nature Reviews Cancer, 2021 - nature.com
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Emerging role of tumor cell plasticity in modifying therapeutic response
Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …
have proposed that acquisition of resistance may result from genetic mutations. However …
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
Immune resistance in lung adenocarcinoma
M Spella, GT Stathopoulos - Cancers, 2021 - mdpi.com
Simple Summary Lung adenocarcinoma (LUAD) is the major subtype of lung cancer and
represents the deadliest human cancer, affecting current-, ex-, and even non-smokers …
represents the deadliest human cancer, affecting current-, ex-, and even non-smokers …